Bill & Melinda Gates Foundation

Hyperfine Research Inc. specializes in developing portable magnetic resonance imaging (MRI) scanners, aimed at making medical imaging more accessible. Founded in 2014 and based in Guilford, Connecticut, the company focuses on general anatomical brain imaging and addresses various medical conditions, including headaches, strokes, non-specific muscle weakness, encephalopathy, spinal cord compressions, diabetic foot disease, and musculoskeletal trauma. Within a year of its establishment, Hyperfine successfully produced its first images, and it has since improved the quality and functionality of its imaging technology. The company’s mission is to democratize healthcare by ensuring that medical imaging is available to people worldwide.

The Medicines for All Institute, operating under the auspices of the Virginia Commonwealth University School of Engineering.

Kallyope Inc. is a biotechnology company based in New York that focuses on the gut-brain axis, the complex communication network between the gastrointestinal tract and the brain. Founded in 2014, Kallyope develops innovative therapeutics and consumer products aimed at enhancing human health and nutrition. The company leverages advanced technologies in sequencing, computational biology, neural imaging, and human genetics to gain insights into gut-brain biology. This understanding allows Kallyope to engage in drug discovery efforts that target the fundamental processes of human physiology, with the potential to transform approaches to health and nutrition.

Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, focused on developing therapeutic products to treat and prevent serious infectious diseases. The company employs a combination of innovative technologies and scientific expertise to enhance the immune response against pathogens. Its pipeline includes several product candidates, such as VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for HIV, and VIR-2020 for tuberculosis. Vir's approach integrates various technology platforms, including antibodies, T cells, and small interfering RNA, to manipulate pathogen-host interactions. The company collaborates with multiple organizations, including the Bill & Melinda Gates Foundation, the National Institutes of Health, and several pharmaceutical companies, to advance its research and development efforts. Additionally, Vir has established agreements for the manufacturing of SARS-CoV-2 antibodies, positioning itself to address emerging infectious diseases. Founded in 2016, Vir Biotechnology aims to make significant advancements in the fight against viral diseases.

Smart Immune is a clinical-stage biotechnology company focused on developing the next generation of hematopoietic stem cell-based biotherapies to change prognosis and life quality for patients with devastating diseases. The company first cell therapy program is based on T cell progenitors or ProTcellsTM (CD7+/CD34- ; CD5- cells) curative power to enable a short, polyclonal and safe post transplantation immune recovery. This program be completed by integrative developments from targeted conditioning to gene therapy and genome editing enabling clinicians to access new generation treatments for a wide variety of inherited blood disorders and blood cancers.

​Osivax is a developer of immunotherapy vaccines intended to facilitate the treatment of infectious diseases. The company's vaccines expedite the uptake into dendritic cells and increase the immunogenicity of the natural protein to trigger a more effective immune response, including an unprecedented CD8 T cell activation, enabling medical practitioners to treat patients with cancer as well as influenza, malaria and other infectious diseases effectively.

SpyBiotech Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in the development of innovative vaccines through its proprietary biotechnology platform. The company utilizes a unique molecular superglue to bond antigens to viruses and other particles, facilitating the rapid creation of vaccines aimed at a variety of diseases. This advanced technology enables medical institutions and research centers to produce next-generation vaccines that demonstrate improved efficacy and reduced development time, thereby enhancing the overall vaccine development process.

UW Medicine Health System is headquartered in the United States. UW Medicine Health System operates as a subsidiary of University of Washington.

VisualDx is an award-winning diagnostic clinical decision support system designed to enhance diagnostic accuracy, aid therapeutic decisions, and improve patient safety. VisualDx combines the world's best curated medical image library with a powerful search engine to give clinicians patient-specific answers in seconds. VisualDx is used by more than 2,300 hospitals, clinics and medical schools around the world.

Sapient enables the discovery of circulating biomarkers at unprecedented speed and scale. Their platform combines advanced mass spectrometry technologies, computational learning, and the world’s largest proprietary human chemical database to deliver actionable insights that accelerate drug creation. Their methods reduce the time and complexity of biomarker discovery at any phase, helping sponsors select and optimize the best drug candidates for clinical advancement.

Nutreco is a global leader in animal nutrition and aquafeed, headquartered in Amersfoort, Netherlands. The company provides advanced nutritional solutions, focusing on quality, innovation, and sustainability throughout its operations. With over 100 years of experience, Nutreco specializes in developing products and services for livestock farming and aquaculture, including animal nutrition and fish feed. Its expertise in research and raw material procurement allows Nutreco to deliver effective solutions that support food production for millions of consumers worldwide.

Flywheel Exchange LLC develops cloud scale data management platform for medical imaging core facilities, and academic and clinical research teams. The company offers tools, such as the flywheel web interface, a graphical user interface; the flywheel command line interface for uploading and downloading files, start jobs, and build gears; software development kits (SDK) for Python 2 and 3, Matlab, and R; and Flywheel Reaper for instrument integration. The company was incorporated in 2012 and is based in Minneapolis, Minnesota.

Phase Genomics, Inc. is a biotechnology company founded in 2015 and located in Seattle, Washington. The company specializes in advanced genomic technologies, particularly ProxiMeta Hi-C genome assembly and metagenome deconvolution. Its mission is to assist scientists in making significant discoveries by delivering highly complete and accurate genomes and metagenomes. Through its innovative approaches, Phase Genomics aims to enhance the understanding of complex biological systems, facilitating research in various fields of life sciences.

Cardea Bio Inc. is a biotechnology company based in San Diego, California, that specializes in the development, manufacturing, and commercialization of graphene-based digital biosensor hardware, software, and molecular infrastructure. Founded in 2013, the company focuses on enhancing precision healthcare through innovative products that improve the ease, speed, and cost of diagnostics. Its insight biosensors utilize graphene to convert biomolecular interactions into digital signals, facilitating direct access to biological data. Cardea offers various products, including the AGILE R100 for small molecule drug discovery and the AGILE R200, an automated high-throughput screening solution. The company's technology enables real-time analysis of biological signals, which is valuable for life sciences and healthcare applications. Cardea Bio also provides diagnostic tests for conditions such as Lyme disease, contributing to advancements in biomolecular analysis and antibody development.

Oxitec is a biotechnology company focused on developing environmentally friendly solutions for controlling insect pests that transmit diseases and damage crops. Founded in 2002 and based in Oxford, United Kingdom, the company utilizes proprietary technology derived from research at the University of Oxford. This technology enhances the traditional Sterile Insect Technique (SIT) by integrating genetics and molecular biology, making it more cost-effective and safe for a wider range of insect pests. Oxitec offers various genetically modified strains, including Aedes aegypti and Aedes albopictus, which target disease-carrying mosquitoes, as well as strains for agricultural pests like the Diamondback moth and Pink bollworm. These innovations aim to provide targeted, non-toxic, and scalable pest control solutions that protect public health, agricultural productivity, and ecosystems. The company also operates a mosquito production facility in Piracicaba, Brazil, contributing to its global efforts in pest management.

Lumen helps educational institutions reduce textbook costs and improve student success using open educational resources and learning analytics. It creates affordable digital course materials using open educational resources (OER). Every Lumen OER course is designed to improve learning and replace expensive textbooks in high-enrollment college courses. Adding timely updates, learning design, and technical support to OER, Lumen makes the transition to open content simple, reliable, and effective for instructors and students. It was founded in 2013 and is headquartered in Portland, Oregon.

Interise is a small and medium businesses company located in Boston.

Yemaachi Biotechnology uses cutting-edge immunogenomics, bioinformatics, and artificial intelligence to accelerate the development of cancer detection and cure strategies for lowering the economic burden of cancer.

Butterfly Network designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. Jonathan M. Rothberg, Nevada Sanchez, and Tyler S. Ralston founded it in 2011, with its headquarters in Guilford in Connecticut.

Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company specializing in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to address life-threatening infections. The company's lead candidate, AR-301, is a fully human IgG1 mAb currently undergoing Phase III trials for treating lung infections linked to S. aureus alphatoxin. Additionally, Aridis is developing several other mAb candidates, including AR-105, in Phase II trials for P. aeruginosa infections, and AR-101, which targets hospital-acquired pneumonia caused by P. aeruginosa serotype O11. Other projects include AR-401, in preclinical stages for Acinetobacter baumannii infections, and AR-201, a preclinical IgG1 mAb for respiratory syncytial virus. The company also has AR-501, an anti-infective therapy in Phase I/IIa clinical trials aimed at managing chronic lung infections in cystic fibrosis patients, as well as acute pneumonia in hospital-acquired pneumonia and ventilator-associated pneumonia settings. Founded in 2003, Aridis is headquartered in San Jose, California.

Particles for Humanity transforms early-stage medical technology into products for people living in low-resource settings. Its development plans include a portfolio of products for improving vaccination and reducing malnutrition. Its rigorous product development process is based on end-user input and is focused on financially sustainable product opportunities.

Evotec is a global drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in various therapeutic areas, including neuroscience, diabetes, oncology, infectious diseases, and pain and inflammation. It offers a range of services such as fee-for-service drug discovery, integrated collaborations, and development partnerships, with a significant portion of its revenue generated from shared research and development activities. Evotec has established numerous long-term alliances with major industry players and is actively involved in both clinical and pre-clinical development programs. The company also operates a segment focused on biologics, providing contract development and manufacturing organization services. Through its expertise and advanced technologies, Evotec aims to deliver differentiated therapeutics and drive the progress of drug development across multiple fields.

TomorrowNow is a global non-profit helping vulnerable communities adapt to climate change.

Elarex is a Canadian healthcare technology company commercializing its proprietary PT120 formulation technology which has proven to stabilize biologicals (including live vaccines!) so that they are as effective when stored at 40C as if they had been stored at -80C.

Providence Therapeutics Inc. is a biotechnology company based in Toronto, Canada, founded in 2015. The company specializes in the development and production of messenger ribonucleic acid (mRNA) vaccines formulated in lipid nanoparticles. Its portfolio includes PTX-101, a personalized mRNA cancer vaccine aimed at treating advanced ovarian cancer, and various COVID-19 vaccines, including PTX-COVID19-B and PTX-COVID19-T, which target the coronavirus and elicit immune responses against the virus. Providence Therapeutics is committed to creating safe and effective therapies to address unmet medical needs, particularly in oncology and infectious diseases, thereby enhancing the quality of life for patients.

MYDAWA is a new and innovative service that allows anyone buy wide range of high quality medication and wellness products affordably and conveniently from your mobile phone.

Schrödinger is a healthcare software company that specializes in computational drug design, serving the biopharmaceutical and biotechnology sectors. Founded in 1990, the company operates through two main segments: Software and Drug Discovery. Its software solutions facilitate drug discovery processes for pharmaceutical and industrial clients, as well as academic and governmental research institutions. In addition to software sales, Schrödinger engages in drug discovery through its own preclinical and clinical programs, often collaborating with other organizations. The company is committed to advancing its computational platform by investing in scientific research and talent, and it has established partnerships and collaborations across more than 70 countries. With a workforce of over 400 employees, Schrödinger continues to influence the life sciences and materials science industries through innovative approaches to drug discovery.

Brightseed, Inc. is a biotechnology company that specializes in discovering clinically beneficial molecules found in plants through its innovative Forager platform. Founded in 2017 and based in San Francisco, California, the company employs artificial intelligence and machine learning algorithms to screen plant genes, identifying the most effective sources for addressing various health conditions. By uncovering naturally occurring compounds with potential health benefits, Brightseed aims to enhance the quality of life and support chronic disease management. The company’s mission is to strengthen the connection between people and plants, ultimately facilitating a healthier future for individuals and communities.

Reithera Srl is a company devoted to develop and produce biopharmaceutical products based on gene delivery technologies for advanced therapies, in order to prevent and treat several serious or life-threatening diseases.

Avanti Platform is an open-access digital financial spine, flexible enough for users and partners to create, curate and deploy the financial products

Biotalys is a green biotech company that employs its proprietary Agrobody technology platform to develop crop protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combine the high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications. It was incorporated in 2012 and is based in Ghent, Belgium.

Exscientia is applying AI and big data processing to accelerate drug discovery and development. At the forefront of small molecule drug discovery. They are the first company to automate drug design, surpassing conventional human endeavor. Their AI-driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. With better information to hand than any researcher could acquire individually, their knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay. With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals. Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.

Avanti Platform is an open-access digital financial spine, flexible enough for users and partners to create, curate and deploy the financial products

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.

Exscientia is applying AI and big data processing to accelerate drug discovery and development. At the forefront of small molecule drug discovery. They are the first company to automate drug design, surpassing conventional human endeavor. Their AI-driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. With better information to hand than any researcher could acquire individually, their knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay. With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals. Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.

Particles for Humanity transforms early-stage medical technology into products for people living in low-resource settings. Its development plans include a portfolio of products for improving vaccination and reducing malnutrition. Its rigorous product development process is based on end-user input and is focused on financially sustainable product opportunities.

Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. tHEY were founded on breakthrough computationally-designed virus-like particle technology, exclusively licensed for a variety of infectious disease indications from the Institute for Protein Design at the University of Washington.

Ilara Health brings accurate and affordable diagnostics to rural Africans through miniature, AI-powered diagnostic devices that are integrated via a proprietary technology platform and distributed directly to primary care doctors.

Evotec is a global drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in various therapeutic areas, including neuroscience, diabetes, oncology, infectious diseases, and pain and inflammation. It offers a range of services such as fee-for-service drug discovery, integrated collaborations, and development partnerships, with a significant portion of its revenue generated from shared research and development activities. Evotec has established numerous long-term alliances with major industry players and is actively involved in both clinical and pre-clinical development programs. The company also operates a segment focused on biologics, providing contract development and manufacturing organization services. Through its expertise and advanced technologies, Evotec aims to deliver differentiated therapeutics and drive the progress of drug development across multiple fields.

Atomwise Inc. is a deep learning AI technology for structure-based small molecule drug discovery. Atomwise performs hundreds of projects per year in partnership with some of the world’s largest pharmaceutical and agrochemical companies, as well as more than 200 universities and hospitals in 40 countries. Its speed and accuracy make it the most advanced technology for small molecule binding affinity prediction. AtomNet, its AI platform built for drug discovery contains more than 16 billion molecules for virtual screening.

Daré Bioscience is a healthcare company committed to the development and commercialization of innovative products in women’s reproductive health.

Sapient enables the discovery of circulating biomarkers at unprecedented speed and scale. Their platform combines advanced mass spectrometry technologies, computational learning, and the world’s largest proprietary human chemical database to deliver actionable insights that accelerate drug creation. Their methods reduce the time and complexity of biomarker discovery at any phase, helping sponsors select and optimize the best drug candidates for clinical advancement.

E25Bio specializes in the development of rapid diagnostic tests for epidemic fever viruses. It is dedicated to preventing severe downstream health outcomes with the use of mobile, fast, real-time reporting to create unprecedented large datasets to guide informed and timely responses for the control of disease spread. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company committed to discovering and developing novel products to prevent and treat infectious diseases.

A-Alpha Bio, Inc., founded in 2017 and based in Seattle, Washington, specializes in synthetic biology with a focus on drug development that targets multiple proteins. The company's flagship platform, AlphaSeq, offers innovative cell-based tools for quantitative and high-throughput measurement of protein interactions. This technology accelerates processes such as target discovery, library screening, and preclinical drug characterization, addressing significant bottlenecks in the industry. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in enhancing binding and specificity for various target proteins. The team comprises experts in synthetic biology, structural biology, and next-generation sequencing, all dedicated to advancing drug discovery methodologies.

Daré Bioscience is a healthcare company committed to the development and commercialization of innovative products in women’s reproductive health.

IBM is a global technology and innovation company headquartered in Armonk, New York, employing over 400,000 individuals across 170 countries. The company provides a diverse array of technology and consulting services, including middleware, predictive analytics, software development, and advanced computing solutions, such as servers and supercomputers. IBM's Global Services division includes Global Business Services and Global Technology Services, which assist clients in managing their IT operations. With a commitment to research and development, IBM invests over $6 billion annually and holds a leadership position in patents, having garnered numerous accolades, including recognition for its contributions to technology and science. The company is known for its pivotal innovations, including the personal computer, the SABRE travel reservation system, and the Watson computing system. IBM continues to leverage its extensive expertise to help organizations navigate the complexities of a digitally interconnected world.

Montreal Heart Institute is a specialty hospital dedicated to the development of cardiology.

Particles for Humanity transforms early-stage medical technology into products for people living in low-resource settings. Its development plans include a portfolio of products for improving vaccination and reducing malnutrition. Its rigorous product development process is based on end-user input and is focused on financially sustainable product opportunities.

Vaxxas Pty. Ltd. develops and commercializes vaccine delivery technologies. It offers Nanopatch platform that induces immune system activation by targeting vaccine to the abundant immunological cells below the surface of the skin. Vaxxas Pty. Ltd. was incorporated in 2011 and is based in Sydney, Australia with an additional office location in Cambridge, Massachusetts.

INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. INOVIO is the first and only company to have clinically demonstrated that DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. Specifically, INOVIO's lead candidate VGX-3100, currently in Phase 3 trials for precancerous cervical dysplasia, demonstrated it destroyed and cleared high-risk HPV 16 and 18 in a Phase 2b clinical trial. High-risk HPV is responsible for 70% of cervical cancer, 90% of anal cancer, and 69% of vulvar cancer.

Centre for Innovation in Regulatory Science is a neutral, independently managed UK-based subsidiary company, forming part of the Clarivate Analytics group. CIRS provides an international forum for industry, regulators, HTA and other healthcare stakeholders to meet, debate and develop regulatory and reimbursement policy through the innovative application of regulatory science and to facilitate access to medical products. This is CIRS’ purpose. CIRS is operated solely for promotion of its purpose. The organisation has its own dedicated management and advisory boards, and its funding is derived from membership dues, related activities, special projects and grants.

Biological Dynamics Inc. is an early-stage company based in San Diego, California, that focuses on developing a proprietary technology platform utilizing AC Electrokinetic technology for the direct and selective capture of large necrotic particles from physiological solutions, including whole blood, serum, and plasma. This innovative platform allows for the rapid extraction of large molecular weight particles that would not naturally settle. The company offers a range of diagnostic solutions, including the TR(ACE) Assay for monitoring treatment response and tumor burden across various cancers, as well as liquid biopsy testing for personalized medicine applications. Additionally, Biological Dynamics provides clinical laboratory services that encompass molecular and next-generation sequencing. Their technology supports various medical needs, including autoimmune disorders, transplant rejection, infectious diseases, and brain injuries, while also aiding in drug development for conditions like Alzheimer's disease. Founded in 2008, Biological Dynamics aims to enhance disease detection and intervention, ultimately improving patient outcomes and reducing healthcare costs.

PiQuant provides component detecting sensor and device based on spectroscopy. - High Sensitivity : PiQuant sensor can detect up to molecular unit - Small Size : PiQuant provides a sensor the size of a thumb and a detecting device the size of a hand can hold - Affordable Price : PiQuant offers less than one-tenth of the price of a conventional sensor.

Macro-Eyes, Inc. is a machine learning company focused on enhancing access to healthcare through its innovative solutions. Its primary product, Sibyl, employs artificial intelligence for intelligent patient scheduling, which has shown a capability to improve patient utilization by 15%, enabling healthcare providers to see more patients without extending clinical hours. This technology is built on extensive research and deployment of AI for clinical decision support at prominent institutions, including Stanford University and major health systems in the United States. The company has garnered support from the Bill & Melinda Gates Foundation to develop a predictive supply chain for health, aimed at optimizing resource allocation at individual health facilities and pharmacies to prevent stock-outs and reduce waste. Additionally, Macro-Eyes is collaborating with the California Primary Care Association to implement Sibyl across 1,800 health facilities, thereby furthering its mission to increase access to life-saving care.

VisualDx is an award-winning diagnostic clinical decision support system designed to enhance diagnostic accuracy, aid therapeutic decisions, and improve patient safety. VisualDx combines the world's best curated medical image library with a powerful search engine to give clinicians patient-specific answers in seconds. VisualDx is used by more than 2,300 hospitals, clinics and medical schools around the world.

Techlets is a provider of a suite of products in the AI-driven MarTech (Marketing Technology). Core product is, Walee - an everyday trade app which enables businesses looking to sell online, and social influencers looking to work with businesses, connect, contract, collaborate and pay each other through an AI-driven matchmaking and financial services engine. Walee has Pakistan's largest and fastest growing influencer network.

OneGoal offers that solution at a low cost and makes graduation a reality for all students. OneGoal collaborate closely with public schools in low-income communities, providing teachers with a robust curriculum, technology, training and coaching to implement our three-year model with a group of 25 students (Fellows) per cohort. Teachers support the same group of Fellows beginning in their junior year of high school and bridge the gap through their first year of their postsecondary education.

Thirty years ago, the women’s funding movement was a gathering of about 20 leaders who were convinced that philanthropy and social change needed to more fully recognize and include women’s voices. Learn more about their unique history and the efforts of women across centuries to spark greater investment in issues affecting women and girls. Today, Women’s Funding Network is a growing community of more than 160 women’s funds and foundations spanning 30 countries. Their latest annual report and impact reports share stories, data, and more about how their Network is making a difference locally, regionally, and globally. Serving this growing community is the task of a diverse team, including their talented staff and their Board of Directors comprised of member representatives, visionary supporters, and thought leaders from around the world. Will you join us in creating a movement of women-led change? Please consider making a gift or becoming a member today.

SurveyAuto has developed an advanced platform to collect reliable data from the field, especially in the developing countries. The platform combines recent advances in Artificial Intelligence (machine learning) with smartphone applications to collect high quality data. SurveyAuto uses machine learning on satellite imagery to accurately identify survey targets, tracks and monitors enumerators in real-time using smartphone applications, and uses speech and image analysis to automatically analyse the quality of collected data.

Almac Group is a contract development and manufacturing organization that provides a wide array of integrated services to the pharmaceutical and biotechnology sectors. Headquartered in Craigavon, Northern Ireland, the company operates globally, with facilities in the UK, Ireland, the United States, and Asia. Almac Group specializes in various aspects of the biopharmaceutical product lifecycle, offering services such as research and development, biomarker discovery, API manufacture, formulation development, clinical trial supply, and companion diagnostic development. They focus on both the discovery and preclinical stages of drug development, often partnering with pharmaceutical companies to advance innovative cancer treatments. With over 4,500 skilled employees, Almac Group emphasizes continuous investment in state-of-the-art technologies to enhance clinical trial management and drug manufacturing processes, ensuring comprehensive support throughout product development and commercialization.

Landcent accelerates the fight against global infectious diseases, by developing & delivering affordable, sustainable solutions, that are safe to use at scale.

MedinCell S.A. is a pharmaceutical company based in Jacou, France, that specializes in developing long-acting injectable drug delivery systems using its proprietary BEPO technology. This innovative approach employs biocompatible materials to create formulations that allow for controlled and sustained release of active pharmaceutical ingredients. The company is advancing several product candidates, including mdc-IRM, a subcutaneous injection for schizophrenia currently in Phase III trials, and mdc-CWM, an intra-articular injection aimed at treating pain and inflammation. Additionally, MedinCell is exploring various formulations in research, such as mdc-WWM for contraception and mdc-ANG for central nervous system disorders. The firm focuses on optimizing the efficiency and accessibility of medical treatments across different therapeutic areas through its ongoing research and development efforts.

GiveIndia operates as a most trustworthy giving platform for donors. With contributions of over 300 crores made to our 200+ vetted and trusted nonprofits, our giving community of 1M+ donors has impacted lives of 4M+ people across 23 states in India.

RJH Biosciences focus on development of transfection reagents and delivery agents for nucleic acids. The company distributes its products via its website and undertakes projects on new medical treatments.

BCD Bioscience, Inc. designs and develops an oligosaccharide library and a roadmap that connects precise carbohydrate structures with their functions as prebiotics and immunomodulators to develop pharmaceutical and food ingredients. It offers a platform for creating and commercializing novel prebiotics, synbiotics, and immuno- modularity therapies for human and animal health. BCD Bioscience, Inc. was formerly known as Calyxo Biosystems, Inc. and changed its name to BCD Bioscience, Inc. in November 2019. The company was incorporated in 2019 and is based in Davis, California.

Enesi Pharma is an innovative pharmaceutical company developing novel products with potential to transform performance and delivery of vaccines and make a material impact on global healthcare. The company’s primary focus is the development of novel solid dose vaccines against a range of infectious and other select diseases, working in partnership with global companies, government agencies and non-governmental organizations.

Credence MedSystems is a drug delivery and specialty pharmaceutical company focused on delivering medications safely for the benefit of our patients, caregivers and partners. Credence MedSystems has changed the paradigm for drug manufacturers commercializing an injectable drug in a differentiated delivery system. The award-winning Companion Safety Syringe System combines a fully compliant, best-in-class injectable drug delivery system with a vastly simplified path to market for our pharma/biotech partners. This is called Innovation Without Change because we offer the innovation of the final device without the change that customarily accompanies combination product development.

Clayton County Public Schools is a public school district

Lyndra Therapeutics is a biotechnology company focused on developing ultra-long-acting oral medications designed to replace daily pill regimens. By providing sustained-release therapies that can be administered weekly or even monthly, the company aims to enhance medication adherence and improve health outcomes. Their innovative approach includes polypill strategies that consolidate multiple medications into a single dose, thereby increasing safety and efficacy while potentially reducing overall healthcare costs. Lyndra Therapeutics is actively developing treatments for a range of conditions, including Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric conditions, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Established in 2015 and headquartered in Watertown, Massachusetts, the company seeks to make a significant impact on global health through its advanced therapeutic solutions.

Biological Dynamics Inc. is an early-stage company based in San Diego, California, that focuses on developing a proprietary technology platform utilizing AC Electrokinetic technology for the direct and selective capture of large necrotic particles from physiological solutions, including whole blood, serum, and plasma. This innovative platform allows for the rapid extraction of large molecular weight particles that would not naturally settle. The company offers a range of diagnostic solutions, including the TR(ACE) Assay for monitoring treatment response and tumor burden across various cancers, as well as liquid biopsy testing for personalized medicine applications. Additionally, Biological Dynamics provides clinical laboratory services that encompass molecular and next-generation sequencing. Their technology supports various medical needs, including autoimmune disorders, transplant rejection, infectious diseases, and brain injuries, while also aiding in drug development for conditions like Alzheimer's disease. Founded in 2008, Biological Dynamics aims to enhance disease detection and intervention, ultimately improving patient outcomes and reducing healthcare costs.

A biotechnology company focused on the discovery of novel vaccines and therapeutics for emerging infectious diseases. It antiviral pipeline includes unique pan-filovirus antibody candidates, vaccines and a variety of other product candidates for emerging viruses.

Northwest Evaluation Association (NWEA) is a not-for-profit organization committed to helping school districts throughout the nation improve learning for all students. NWEA partners with more than 2,200 school districts representing more than three million students. As a result of NWEA tests, educators can make informed decisions to promote your child’s academic growth.

Univercells SA, founded in 2013 and based in Gosselies, Belgium, specializes in the design, development, and implementation of single-use bioprocess solutions for biomanufacturing. The company offers a comprehensive range of services, including the design and construction of manufacturing facilities, as well as the maintenance and supply of bulk active pharmaceutical ingredients (APIs). With a focus on vaccines and biologics, Univercells employs innovative engineering techniques that significantly reduce investment needs by over 75% and lower production costs by up to 90%. Their approach integrates three manufacturing steps—cell culture under perfusion, clarification, and capture—into a simulated continuous mode, enhancing efficiency in the production of antibodies, proteins, and vaccines. Additionally, Univercells has established a strategic partnership with Takeda Pharmaceutical Company to further advance its capabilities in the biomanufacturing sector.

Emory University, established in 1836 and located in Atlanta, Georgia, is a prominent non-profit institution known for its exceptional liberal arts colleges, graduate and professional schools, and a leading healthcare system. The university boasts a diverse portfolio exceeding $7 billion, managed by Emory Investment Management, which oversees various investment strategies to ensure long-term growth and sustainability. Emory attracts significant research funding, exceeding $500 million annually, while maintaining a strong commitment to teaching and collaboration across its schools and centers. The institution's rich legacy is reflected in its dynamic community of scholars, faculty, and students, who contribute to its mission of academic excellence and societal impact. Emory’s strategic investment approach not only supports its educational and healthcare initiatives but also enhances its ability to recruit top talent and uphold its reputation as a global leader in higher education.

Sidai is a fully vertically-integrated company supplying quality livestock and crop inputs and training to farmers and pastoralists across Kenya. The company operates through a network of branded, professionally-staffed, company-managed and franchised retail outlets, stockists and field staff. Sidai has a unique ‘last-mile’ service delivery model that also reaches pastoralists and farmers in remote and under-served locations.

Qloudlab is a pioneering company that has developed Sceptre, the world's first touchscreen-based biosensor platform designed for Point-of-Care diagnostics. This modular and cost-effective technology allows for the simultaneous performance of various tests, including blood, urine, saliva, and skin tests, all on a single mobile platform. By integrating advancements in smartphone technology, healthcare, and cloud solutions, Qloudlab aims to enhance the accessibility and efficiency of diagnostic testing. The company focuses on simplifying the testing process for both patients and healthcare professionals, making healthcare more adaptable to individual lifestyles.

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. The company also develops next-generation transgenic mice that provide a source of fully-human antibodies for the discovery of therapeutic antibody candidates. It has a discovery partnership agreement with Eli Lilly and Company for the discovery of various targets. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.

Making nature accessible and affordable for a growing society.It is estimated that the world’s population will increase by more than 35% by 2050, reaching 9 billion people. Crop production will need to more than double in order to feed these people and meet the consumer needs of a developing world. With very little land remaining for agricultural expansion, they as a society need to find ways to maximize the use of their world’s resources. Plants produce a variety of rare natural products which are used in their daily lives as flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals and agricultural chemicals. They strive to reduce their dependence on land- and resource-intensive practices by recreating natural processes through biotechnology.

Phase Genomics, Inc. is a biotechnology company founded in 2015 and located in Seattle, Washington. The company specializes in advanced genomic technologies, particularly ProxiMeta Hi-C genome assembly and metagenome deconvolution. Its mission is to assist scientists in making significant discoveries by delivering highly complete and accurate genomes and metagenomes. Through its innovative approaches, Phase Genomics aims to enhance the understanding of complex biological systems, facilitating research in various fields of life sciences.

Particles for Humanity transforms early-stage medical technology into products for people living in low-resource settings. Its development plans include a portfolio of products for improving vaccination and reducing malnutrition. Its rigorous product development process is based on end-user input and is focused on financially sustainable product opportunities.

Macro-Eyes, Inc. is a machine learning company focused on enhancing access to healthcare through its innovative solutions. Its primary product, Sibyl, employs artificial intelligence for intelligent patient scheduling, which has shown a capability to improve patient utilization by 15%, enabling healthcare providers to see more patients without extending clinical hours. This technology is built on extensive research and deployment of AI for clinical decision support at prominent institutions, including Stanford University and major health systems in the United States. The company has garnered support from the Bill & Melinda Gates Foundation to develop a predictive supply chain for health, aimed at optimizing resource allocation at individual health facilities and pharmacies to prevent stock-outs and reduce waste. Additionally, Macro-Eyes is collaborating with the California Primary Care Association to implement Sibyl across 1,800 health facilities, thereby furthering its mission to increase access to life-saving care.

DelSiTech, Ltd. engages in developing and licensing long-term controlled drug delivery implants, subcutaneous, and intramuscular formulations. It offers silica-based implants, subcutaneous, and intra-muscular injectable technology for controlled release of small molecular drugs and biopharmaceuticals. The company’s drug delivery products inject proteins, polysaccharides, and viruses. DelSiTech, Ltd. was founded in 2001 and is based in Turku, Finland.

Lyell Immunopharma is focused on advancing the science of T-cell differentiation, functionality, and specificity so that they can develop curative treatments for human diseases. Lyell Immunopharma is headquartered in South San Francisco, California.

City Schools is committed to ensuring that all students graduate from high school ready for college, career training, and life success in the 21st century. This work, guided by priorities PDF icon set by the Baltimore City Board of School Commissioners, includes - Implementation of new curricula aligned to Maryland's College and Career-Ready Standards, incorporating the Common Core State Standards - Expansion of systems to ensure effective instruction and leadership across the district, including new evaluations for teachers and school leaders - Launch of the design phase for modern, high-quality school buildings under the 21st-Century Buildings Plan.

Oxitec is a biotechnology company focused on developing environmentally friendly solutions for controlling insect pests that transmit diseases and damage crops. Founded in 2002 and based in Oxford, United Kingdom, the company utilizes proprietary technology derived from research at the University of Oxford. This technology enhances the traditional Sterile Insect Technique (SIT) by integrating genetics and molecular biology, making it more cost-effective and safe for a wider range of insect pests. Oxitec offers various genetically modified strains, including Aedes aegypti and Aedes albopictus, which target disease-carrying mosquitoes, as well as strains for agricultural pests like the Diamondback moth and Pink bollworm. These innovations aim to provide targeted, non-toxic, and scalable pest control solutions that protect public health, agricultural productivity, and ecosystems. The company also operates a mosquito production facility in Piracicaba, Brazil, contributing to its global efforts in pest management.

Recursion Pharmaceuticals is a biotechnology company based in Salt Lake City. Recursion combines experimental biology, automation, and artificial intelligence in a massively parallel system to quickly and efficiently identify treatments for any disease which can be modeled at the cellular level. From its initial and continued focus on drug repurposing to treat rare diseases, Recursion has broadened its platform to probe rich data from high-throughput automated screens for a number of indications, including aging, inflammation, infectious disease, and immunology. Recursion is aggressively leveraging technology to build a robust and reliable map of human cellular biology, which will enable a radical shift in the pace and scale at which new treatments will benefit patients.

Full Investment Portfolio Cash and Short Term Investment fund: 23.59% Global Equity and Convertible Securities: 38.22% Government, mortgage and corporate debt fund: 8.60% Private equity: 6.12% Real Estate: 0.72% Infrastructure: 1.11% Return Hedge Fund: 17.91% Absolute Return fund: 3.74% Founded in 1924, the Scripps Research Institute is a non-profit organisation based in California, United States. The foundation focuses on research and education in the biomedical sciences.

Crane Engineering is a leading provider of high performance fluid systems solutions to a broad range of industries throughout the U.S., Canada and Mexico. Everything we do is about reducing your total cost of ownership and helping you make your fluid systems run better. For over 75 years we've had our customers' backs, providing them with fluid processing know-how and solutions specifically engineered for efficiency and profitability. Working with the world's top fluid technology manufacturers, we bring our customers innovative ideas that make a real difference in performance and help reduce total cost of ownership. At Crane Engineering, we've brought together the people, products, and experience to help you perform better. Leverage their abilities to make the Crane Advantage, your advantage.

Novartis is a multinational healthcare company based in Switzerland, focused on developing innovative solutions to improve patient health worldwide. With a commitment to addressing significant health challenges, Novartis applies its expertise in science and research to discover new medicines and therapies. The company operates various divisions, including Novartis Oncology, which specializes in creating treatments for cancer and related diseases, boasting a pipeline of over 25 new molecular entities aimed at advancing patient care. Additionally, the Genomics Institute of the Novartis Research Foundation plays a crucial role in bridging basic science and drug discovery through advanced technologies and high-throughput screening. Novartis also emphasizes animal health, offering innovative medicines to improve the welfare of pets, farm animals, and fish. Overall, Novartis is dedicated to enhancing the quality of life for both humans and animals through its comprehensive range of healthcare products and services.

Making nature accessible and affordable for a growing society.It is estimated that the world’s population will increase by more than 35% by 2050, reaching 9 billion people. Crop production will need to more than double in order to feed these people and meet the consumer needs of a developing world. With very little land remaining for agricultural expansion, they as a society need to find ways to maximize the use of their world’s resources. Plants produce a variety of rare natural products which are used in their daily lives as flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals and agricultural chemicals. They strive to reduce their dependence on land- and resource-intensive practices by recreating natural processes through biotechnology.

Code.org is a non-profit organization focused on expanding computer programming education in the United States. It aims to integrate computer science into the core curriculum of K-12 education, alongside other STEM subjects. The foundation offers free online courses that utilize open source technology, allowing for widespread access to high-quality educational resources. Its curriculum materials and tutorials are shared under a Creative Commons license, promoting non-commercial use and collaboration. By fostering a greater understanding of computer science, Code.org seeks to prepare students for the demands of a technology-driven world.

Macro-Eyes, Inc. is a machine learning company focused on enhancing access to healthcare through its innovative solutions. Its primary product, Sibyl, employs artificial intelligence for intelligent patient scheduling, which has shown a capability to improve patient utilization by 15%, enabling healthcare providers to see more patients without extending clinical hours. This technology is built on extensive research and deployment of AI for clinical decision support at prominent institutions, including Stanford University and major health systems in the United States. The company has garnered support from the Bill & Melinda Gates Foundation to develop a predictive supply chain for health, aimed at optimizing resource allocation at individual health facilities and pharmacies to prevent stock-outs and reduce waste. Additionally, Macro-Eyes is collaborating with the California Primary Care Association to implement Sibyl across 1,800 health facilities, thereby furthering its mission to increase access to life-saving care.

NemoCare is developing the smartest and most comprehensive patient monitoring and management system. It is an innovative, continuous vital sign data acquisition, analysis and prediction engine that combines unobtrusive wireless wearable sensors and networks, analytical algorithms and big data to provide affordable continuous, high resolution monitoring for all newborns in hospital, and at home. We use design thinking principles to build life-saving technologies that will transform the way healthcare is delivered. Our current area of work is in newborn and maternal care.

Ventria Bioscience, Inc. is a biotechnology company based in Fort Collins, Colorado, specializing in the development, manufacturing, and marketing of health and nutrition products. Founded in 1993, the company focuses on human nutrition and therapeutics, offering a range of products that includes lactoferrin and lysozyme glycoproteins, which are utilized for gastrointestinal health and the dietary management of acute diarrhea, as well as for treating topical infections and fungal conditions. Ventria also provides OptiVERO, a specialized cell culture media for vaccine manufacturing, and operates a BioShare program that grants researchers access to recombinant proteins and peptides for various research applications. The company leverages its patented ExpressTec technology, which enhances recombinant protein yield through a plant-based manufacturing process, enabling the development of new biotherapeutics, vaccines, and other biomanufacturing reagents.